Subject Index to Volume 75

A

***N*-Acetyl-aspartyl-glutamate,** in septohippocampal pathway, 406
Acetylcholine
in control of respiratory central pattern generator, 18–19
interactions with tachykinins, 292
interactions with vasoactive intestinal peptide, 291
in penile erection, 209–210
regulation of gastric acid secretion, 157–158
in septohippocampal pathway, 395–396
colocalizations with neuropeptides, 398
control of release, 403–404
mechanism of action in hippocampus, 404–406
postsynaptic effects on pyramidal hippocampal neurons, 404–405
presynaptic effects, 405–406
transport, vesicular neurotransmitter transporters, 373–374
cloning, 379
inhibition of, 375–376
members of toxin-extruding antiporter superfamily, 381–384
Acetylcholine receptor
aggregation during formation of neuromuscular junction, 353–355, 801–805
agrin in, 353–355, 801–803
stabilization of junctional AChRs, 805
biosynthesis and secretory pathway, 356–357
gene expression, neural regulation, 803–805
gene expression at developing neuromuscular junction, 339–359 *See also* Neuromuscular junction
metabolic stabilization, 357
parietal cell, 163–164
Acetylcholine receptor inducing activity (ARIA), in end-plate-specific acetylcholine receptor gene expression, 346
Acetyl-CoA carboxylase, regulation of concentration by nutritional states, fatty acid synthesis, 58–60
ACTH. *See* Adrenocorticotropic hormone
α-Actin, in differentiated vascular smooth muscle cells, 489–490
Actin filaments, mitroctubule interactions, microtuble-associated proteins in mediation of, 847–848
Adenosine
in local metabolic control of veins, 621–622
in penile erection, 217
Adenosine 3′,5′-cyclic monophosphate, airway actions of vasoactive intestinal peptide, 293–294
Adenosine 5′-diphosphate, in local metabolic control of veins, 621–622
Adenosinetriphosphatase (ATPase)
calcium, renal calcium transport, 460–461
calcium-magnesium, hepatocyte canalicular membrane, 262–263
ectoadenosinetriphosphatase, hepatocyte canalicular membrane, 263–264
hepatocyte canalicular membrane-associated, 261–264
hydrogen-potassium, 167–178
activation of, 175–176
enzymatic properties, 173
functions, 173–175
identification as gastric proton pump, 174–175
inhibition of, 176–178
structure, 168–173
α-subunit, 168–171
β-subunit, 171–172
α,β-subunit associations, 172–173
synthesis and turnover, 176
tertiary structure, 173
transport properties, 173–174
P-type ion-transporting ATPases, hepatocyte canalicular membrane, 261–263
sodium-potassium, hepatocyte canalicular membrane, 261–262
Adenosine 5′-triphosphate
in local metabolic control of veins, 621–622
in penile erection, 217
production, regulation, in transgenic mouse, 673–678. *See also* Transgenic mice
Adenosine 5′-triphosphate citrate lyase, in fatty acid synthesis, 65
Adhesion molecules, in endothelial mechanotransduction, 538
Adipose tissue
GLUT-4 expression, in transgenic mouse, 672–673
in non-insulin-dependent diabetes mellitus, 476–477
Adrenoceptors
on immune system cells, 91–92
in penile erection, 208–209
Adrenocorticotropic hormone
immune system effects, 81–82
in penile erection, 205–206
thermogenesis, 247
Aequorin, measurement of intracellular calcium, 432–435
Age/aging, septohippocampal pathway, 408–409
behavioral studies, 408–409
cholinergic "markers," 408
electrophysiological studies, 409
medial septal neurons in aged animal, 408
Agrin, in acetylcholine receptor protein aggregation during formation of neuromuscular junction, 353–355
Airway function, neuropeptide regulation. *See* Neuropeptides, regulation of airway function; *specific neuropeptides*
Airway inflammation
tachykinins in, 302–303
vasoactive intestinal peptide in, 303–304
Airway reactivity, neuropeptide actions, 284–286, 297–299
Airway secretions, neuropeptide actions, 287–288, 299
Aldosterone, atrial natriuretic peptide regulation, role of PDE2 phosphodiesterases, 734
Allosteric regulators, fatty acid synthesis regulation, 55–56
Alzheimer's disease, septohippocampal pathway in, 409
Amblyopia, 331–332
Amino acids
excitatory, in respiratory central pattern generator, 16–17
inhibitory, in respiratory central pattern generator, 17–18
transport, vesicular neurotransmitter transporters, 372–373
γ-Aminobutyric acid (GABA)
in penile erection, 205–206
in septohippocampal pathway, 396–397, 406
in visual cortex, 115
actions, 117
γ-Aminobutyric acid (GABA) receptors, in visual cortex, 117
Angiogenesis, venous system, 613
Angiotensin-converting enzyme (ACE), degradation of airway neuropeptides, tachykinins, 296–297
Angiotensin II, in local control of venous tone, 633–634
Antidromic mapping, respiratory neurons, 12–13
Arginine residues, role in structure and function of vesicular neurotransmitter transporters, 385–386
Arginine vasopressin. *See* Vasopressin
Arsenazo III, measurement of intracellular calcium, 435–437
Arterial system
hemodynamic forces, 520–521

penis, 192–193
remodeling, flow-dependent, 548
Asialoglycoprotein receptor, 591–604
biosynthesis, 593
endocytic pathway, 597–599
extrahepatic receptor, 603
ligand specificity, 594–596
modulation of expression, 599–603
naturally occurring ligands, 596–597
posttranslational modifications, 593–594
structure, 591–593
targeted delivery, 603–604
Asthma, vasoactive intestinal peptide in, 303–304
Atherosclerosis
alterations in vascular smooth muscle cell differentiated state, 508–509
hemodynamics and focal origin, 548–551
Atrial natriuretic peptide
in local control of venous tone, 635–636
regulation of aldosterone, role of PDE2 phosphodiesterases, 734
renal sodium handling, PDE5 phosphodiesterase and, 738
Autonomic nervous system, innervation of lung, 279

B

***Bacillus* spp.**
multidrug resistance, reserpine in, 381
subtilis, toxicity, 581
thuringiensis, toxicity, 581
Bacteria
toxic effects. *See also* Xenobiotics, bacterial mechanisms, 581
toxin-extruding antiporter (TEXAN) superfamily, vesicular neurotransmitter transporters, 381–384
Basal lamina, in end-plate-specific acetylcholine receptor gene expression, 346–347
Basalocortical pathway, comparison with septohippocampal pathway, 411
Basket cells, in visual cortex, 115–116
Behavioral conditioning, nervous system-immune interactions, 77–78
Behavioral deficits, age-related, 408–409
Behavioral studies, septohippocampal pathway in aging, 408–409
Benzimidazoles, substituted, inhibition of gastric proton pump, 177–178
Bile acids, hepatocyte canalicular membrane adenosine 5′-triphosphate-dependent transport, 266–267
Binding hypothesis, 140
Bioluminescent indicators, measurement of intracellular calcium, 432–435
B1k1 protein, 853
Blood pressure, regulation, PDE3 phosphodiesterase in, 735
BMR protein, mutations, 386
Bordetella pertussis toxicity, 581
Bradykinin, in local control of venous tone, 636–637
Breathing
central control, 1–31
neuromodulators that control central pattern generator, 18–22
neuronal elements, 2–15. *See also* Respiratory neurons
characterization of respiratory neurons, 2–8
location and anatomic organization, 8–12
synaptic connections, 12–15
neurotransmitters involved in respiratory central pattern generator, 16–18
central pattern generator
neuromodulators that control, 18–22
neuronal elements and role in CPG functions, 25–27
neurotransmitters involved in, 16–18
respiratory rhythmogenesis, 22–31
excitatory amino acids in, 16–17
inhibitory amino acids in, 17–18
model of respiratory rhythm generation, 27–31
augmenting patterns, 29–30
decrementing patterns, 30–31
phase-switching neurons, 31
respiratory sequence, 31
neuromodulators that control central pattern generator, 18–22
acetylcholine, 18–19
biogenic amines, 19–20
catecholamines, 20
cholecystokinin, 22
neuropeptides, 20–22
opioid peptides, 20–21
serotonin, 19–20
somatostatin, 22
substance P, 21–22
thyrotropin-releasing hormone, 22
neuronal elements involved in central pattern generator functions, 25–27
neurotransmitters involved in respiratory central pattern generator, 16–18
principles of genesis of rhythmic motor activities, 23
role of intrinsic membrane properties, 23–25
calcium-dependent potassium current, 24–25
noninactivating potassium currents, 25
postinhibitory effects and intrinsic currents, 23–24
Bromocriptine, inhibition of vesicular neurotransmitter transporters, 375
Bronchial asthma, vasoactive intestinal peptide in, 302
Bronchial circulation, neuropeptide actions, 290–291

C

Calcitonin, regulation of renal calcium transport, 452–453
Calcitonin gene-related peptide
in end-plate-specific acetylcholine receptor gene expression, 345–346
in local control of venous tone, 636
in penile erection, 215
Calcium
airway actions of vasoactive intestinal peptide, 294
cellular transport in renal epithelia. *See* Renal calcium transport
intracellular
in endothelial mechanotransduction, 541–542
measurement, 431–443
in local control of venous tone, 628–631
calcium channel blockers and, 629
calcium dependency of venoactive agents, 629–631
calcium fluxes of venous smooth muscle
in hypertension, 631
shear stress and, 631
measurement, 430–443
bioluminescent indicators, 432–435
calcium ion activity vs. calcium concentration, 430–431
calcium-selective microelectrodes, 431–432
electron-probe X-ray microanalysis, 440–442
fluorescent tetracarboxylate indicators, 437–440
fluorine-19 nuclear magnetic resonance, 442–443

intracellular calcium, 431–443
metallochromic indicators, 435–437
regulation of PDE1 phosphodiesterases, 732
Calcium channel(s)
cardiac, control, role of PDE2 phosphodiesterases, 734–735
G protein regulation, 875–877
in penile erection, 208
renal calcium transport, 455–457
voltage-dependent, 875
inhibition, 876
stimulation, 877
Calcium channel blockers, in local control of venous tone, 629
Caldesmon, in differentiated vascular smooth muscle cells, 492–494
Calmodulin
airway actions of vasoactive intestinal peptide, 294
regulation of PDE1 phosphodiesterases, 732
Calponin, in differentiated vascular smooth muscle cells, 492
Carbohydrate, dietary, communication of nutritional status to liver, 53–54
Carboxyl residues, role in structure and function of vesicular neurotransmitter transporters, 385
Cardiac function, PDE3 phosphodiesterase in, 735–736
Catecholamines
in central regulation of nonshivering thermogenesis, 243
in control of respiratory central pattern generator, 20
immunologic effects
in vitro regulation of immune system, 94–96
in vivo, 92–94
secretion, role of PDE2 phosphodiesterases, 734
β-Cell, pancreatic, in non-insulin-dependent diabetes mellitus, 474–476
Cellular differentiation
control mechanisms, skeletal muscle paradigm, 488
vascular smooth muscle. *See* Vascular smooth muscle cell differentiation
Central nervous system
breathing control, 1–31
grafts in, septohippocampal model, 409
neuronal function, role of PDE2 phosphodiesterases, 735
nonsynaptic modulation of neuronal activity. *See* Nonsynaptic interactions
in penile erection, 200–206
cerebral mechanisms, 200–201
neurotransmitters, 201–206
spinal mechanisms, 200
regulation of gastric acid secretion, 156–157
regulation of nonshivering thermogenesis, 243
Central nervous system-immune system interactions, 77–97
anatomic and functional evidence, 86–96
in vitro regulation of immune system by catecholamines, 94–96
in vivo catecholamine effects, 92–94
peptidergic innervation and influences on inflammatory and immune processes, 90–91
presence of adrenoceptors on cells of immune system, 91–92
sympathetic noradrenergic innervation of lymphoid organs, 87–90
evidence for, 77–80
behavioral conditioning, 77–78
CNS lesions and intracerebroventricular infusions, 79–80
stress and psychosocial factors, 78–79
immune system communication with nervous system, 96–97
changes in sympathetic activity after immunologic activation, 96–97
hypothalamic alterations following immunologic activation, 96
neuroendocrine hormone production by immune system, 97
influence of neuroendocrine hormones on immune system, 80–86
adrenocorticotropic hormone, 81–82
glucocorticoids, 80–81
gonadal steroids, 85–86
growth hormone, 83–84
hypothalamo-pituitary-adrenal axis, 80–82
opioid peptides, 82–83
posterior pituitary neurohormones, 86
prolactin, 84–85
thyroid hormones, 85
thyroid-stimulating hormone, 85
Central pattern generator, respiratory. *See* Breathing
Central synaptic transmission, 759–782
chemical synapses in mammalian central nervous system, 760
effect of high-frequency stimulation on presynaptic membrane, 770–771
electrophysiological studies, 771–778
postsynaptic receptor number and quantal size, 773–776
quantal analysis, 771–773
skewed miniature distribution, 776–777
glutamatergic synapses on spines, 761–769
boutons, 761–764
presynaptic organelles including presynaptic grid, 763–764
spines, 764–769
function of, 768–769
number and shape, 764–765
organelles in, 767–768
postsynaptic density and spinules, 766–767
synaptic cleft, 764
synaptic vesicles, 763
introduction, 759–760
long-term potentiation, 778–782. *See also* Long-term potentiation
morphological changes correlated with expected plasticity or long-term potentiation, 770
morphological features of a spine synapse, 782
number of connections between axon and single postsynaptic cell, 769–770
theories of, 773
Chandelier cells, in visual cortex, 116
Chloride, in local control of venous tone, 632–633
Chloride channel(s)
airway actions of vasoactive intestinal peptide, 294
G protein regulation, 878–879
Cholecystokinin
in control of respiratory central pattern generator, 22
in visual cortex, 118
Cholesterol, high-density lipoprotein, in syndrome X, 479–480
Choline acetyltransferase, in septohippocampal pathway, 396
Cloning
vesicular acetylcholine transporters, 379
vesicular monoamine transporters, 377–379
Clostridium spp.
difficile, toxicity, 583
perfringens, toxicity, 583
Complement system, C-9, modulation of epithelial permeability, 574
Coronary heart disease, syndrome X and, 481–483
Corticocortical connections, visual system. *See* Visual system
Corticosteroids
communication of nutritional status to liver, 51–52
thermogenesis, 247
Corynebacterium diphtheriae toxicity, 583
Creatine kinase
in cellular energy metabolism, in transgenic mice, 678–683. *See also* Transgenic mice
regulation of adenosine 5′-triphosphate production in transgenic mice, 673–675
Cyclic nucleotide phosphodiesterases, 725–743
alternative splice variants, 727

clinical studies, 742–743
current concepts for roles and functions, 726
disease and, 741
general structure-function relationships, 740–741
conserved catalytic domain: motifs, 740–741
oligomeric structure, 740
historical perspective, 725–726
inhibitors, 742–743
nonselective, 743
PDE1, 742
PDE3, 742–743
PDE4, 743
PDE5, 743
nomenclature, 726–727
PDE1 family, 727–734
inhibitors, 742
localization, 730–732
number of family members, 727, 730
possible role in olfaction, 733–734
possible role in plasticity, 732
regulation by Ca^{2+}/CaM, 732
regulation by phosphorylation, 732
substrate specificity, 730
PDE2 family, 734–735
PDE3 family, 735–737
inhibitors, 742–743
number of family members and localization, 735
regulation by phosphorylation/dephosphorylation, 736
role in blood pressure regulation, 735
role in cardiac function, 735–736
role in insulin action, 736–737
role in platelet aggregation, 735
substrate specificity, 735
PDE4 family, 737–738
diabetes insipidus and, 741
inhibitors, 743
PDE5 family, 738
inhibitors, 743
PDE6 family, 739–740
retinal disease and, 741
PDE7 family, 740
phosphodiesterase gene families, 726–727
physiological regulation and roles for individual phosphodiesterase isozymes, 727–740. *See also specific isozymes*
PDE1 family, 727–734
PDE2 family, 734–735
PDE3 family, 735–737
PDE4 family, 737–738
PDE5 family, 738
PDE6 family, 739–740
PDE7 family, 740
targets for therapeutic intervention, 741
Cystic fibrosis, vasoactive intestinal peptide in, 302
Cytokines, modulation of epithelial permeability, 569–574
Cytoplasmic linker protein, 852

D

Demyelination, ephaptic transmission in, 695–696
Dendritic bundles, 699
Depth perception, development, 330–331
Desmin, in differentiated vascular smooth muscle cells, 494–495
Diabetes insipidus, PDE4 phosphodiesterase in, 741
Diabetes mellitus, non-insulin-dependent, 474–478
adipose tissue in, 476–477
β-cell in, 474–476
liver in, 477–478
muscle insulin resistance in, 474
Diet, macronutrient composition, regulation of fatty acid synthesis. *See* Fatty acid synthesis, nutritional regulation
1,25-Dihydroxyvitamin D_3, regulation of renal calcium transport, 453–455
Dopamine. *See also* Catecholamines
in penile erection, 202–203
Double-bouquet cells, in visual cortex, 116
Drosophila melanogaster, microtubule-associated proteins from, 849
Dyslipidemia, in syndrome X, 479–480

E

Echinoderms, microtubule-associated proteins from, 850
Ectoadenosinetriphosphatase, hepatocyte canalicular membrane, 263–264
Eicosanoids, in local control of venous tone, 637–639
Electric fields
biological effects, 702–703
in epileptogenesis, 712–713
neuronal growth and structure and, 702
neuron sensitivity to, 699–703
roles of, 703
sensitivity of mammalian cortex, 701–702
tissue conductivity, 699–700
Electron-probe X-ray microanalysis, measurement of intracellular calcium, 440–442
Electrophysiology
septohippocampal pathway in aging, 409
synaptic transmission, 771–778
morphological changes correlated with, 770
postsynaptic receptor number and quantal size, 773–776
quantal analysis at neuromuscular junction, 771–773
skewed miniature distribution, 776–777
theories on synaptic transmission, 773
Endothelial mechanotransduction, 519–551
atherosclerosis, flow dynamics and focal origin, 548–551
blood flow in arterial circulation, 520–521
candidate mechanotransducers, 526–538
adhesion molecules of immunoglobulin superfamily, 538
focal adhesions and integrins, 530–534
G protein-linked receptors, 534–535
mechanosensitive ion channels, 528–530
shear stress-activated potassium channels, 529
stretch-activated ion channels, 529–530
mitogen-activated protein kinase signaling, 535
plasma membrane proteins, 528
structural considerations, 526–528
thrombomodulin, 535, 537–538
flow-dependent arterial remodeling, 548
flow modulation of agonist mass transport and receptor-ligand interactions, 539–541
future directions, 551
hemodynamic force interactions with endothelium, 521–526
cytoskeletal elements and force transmission throughout the cell, 525–526
forces and cell tension, 521–523
force transmission, 522–523
stress, 521–522
signal filtering and adaptation to mechanical stimuli, 526
topography of luminal endothelial surface, 523–525
intracellular calcium, 541–542

morphological responses to shear stress, 521
shear stress-mediated vasoregulation, 544–548
effect of shear stress on calcium fluxes of venous endothelial cells, 631
endothelin-1 in, 546–548
histamine in, 548
nitric oxide in, 544–546
prostacyclin in, 546
temporal considerations of hemodynamic responses, 538–539
transcription factors and stress response elements, 542–544
where mechanotransduction occurs, 526–538
structural considerations, 526–528
Endothelin(s)
endothelin-1, in shear stress-mediated vasoregulation, 546–548
in local control of venous tone, 641–642
in penile erection, 213–214
synthesis in vascular wall, 614
Endothelium-derived relaxing factor
in local control of venous tone, 639–641
synthesis in vascular wall, 614
Energy balance, humoral thermogenesis and, 237–249. *See also* Thermogenesis
Energy metabolism, cellular, insights from transgenic mice. *See* Transgenic mice
Enterochromaffin-like (ECL) cell
histamine release, 158–160
hyperplasia, 160
Enzymes, regulation of concentration by nutritional states, fatty acid synthesis, 57–66
Eosinophil-derived proteins, modulation of epithelial permeability, 570–572
Ephaptic transmission, 694–699
between axons, 695–697
in demyelination, 695–696
in nerve compression, 696–697
in neuromas, 697
background, 694–695
conditions necessary for, 695
dendritic bundles, 699
ephaptic field interactions in normal vertebrates, 697–699
mammalian cerebellar Purkinje cells, 698
Mauthner cell and other teleost systems, 697–698
other parts of mammalian brain, 698–699
in epileptogenesis, 711–712
Epilepsy, 710–714
basic mechanisms, 710–711
field effects in interictal epileptic discharges, 712
gap junctions and ephaptic interactions in epileptogenesis, 711–712
interactions between external electric fields and epileptic activity, 712–713
seizures, 713–714
Epinephrine. *See also* Catecholamines
thermogenesis, 244–245
Epithelial permeability, 561–585
epithelial structure, 562–566
assessing barrier properties, 563–566
electrical methods, 563–565
nonelectrical methods, 565–566
geometry, 562–563
modulation by extracellular macromolecules, 561–585
bacterial xenobiotics, 579–585. *See also* Xenobiotics, bacterial
antibiotics, 579–581
toxins, 581–585
cellular constituents, 574–576
cytokines, 569–574
eosinophil-derived proteins, 570–572
histones, 576
magainins, 578
neutrophil-derived proteins, 572–573
nonbacterial xenobiotics, 576–579
palytoxin, 578–579
protamine, 574–576
proteases, 561–569
thionins, 576–578
T lymphocytes and natural killer cells, 573–574
tumor necrosis-α and interferon-γ, 569–570
Escherichia coli **toxicity,** 583
Extraocular muscle proprioception, 323–334
binocular integration, 327–331
behavioral data, 329–331
depth perception and stereoacuity, 330–331
electrophysiological data, 327–328
orienting behavior, 329–330
visuomotor behavior development, 329
relation to orientation selectivity, 324–326
strabismus and amblyopia, 331–332
Eye movements, orientation selectivity, 324–326

F

Fats, dietary, communication of nutritional status to liver, 54–55
Fatty acid synthase, regulation of concentration by nutritional states, fatty acid synthesis, 61–63
Fatty acid synthesis
nutritional regulation, 47–67
humoral factors communicate nutritional status to liver, 50–55
carbohydrate, 53–54
fatty acids, 54–55
fuels and metabolites, 53–55
hormones in culture, 52–53
hormones in vivo, 50–52
manipulating specific nutrients in diet, 49–50
molecular mechanisms, 55–66
allosteric control, 55–56
common intracellular signaling pathways, 66
phosphorylation-dephosphorylation, 56–57
regulation of enzyme concentration, 57–66
regulation of enzyme concentration, 57–66
acetyl-CoA carboxylase, 58–60
fatty acid synthase, 61–63
glucose-6-phosphate dehydrogenase, 58
malic enzyme, 63–65
other enzymes, 65
L-pyruvate kinase, 60–61
relationship of growth regulation to control of fatty acid synthesis, 66–67
starvation-refeeding paradigm, 49
overview of pathway, 47–48
physiological role of de novo fatty acid synthesis, 48–49
regulation, relevance to caloric homeostasis, 49
Feedback corticocortical connections, 108–110
are they more diffuse, 128–129
axonal bifurcation, 129
distribution of cells and axon terminals, 128
functional aspects assessed by inactivation or lesion studies, 132–133
reciprocity between cortical connections at level of cell patch, 128–129
visuotopic organization, 122
Feedforward corticocortical connections, 108–110
functional aspects assessed by inactivation or lesion studies, 130–132

patchy organization, 123–129
axon terminals, 126–127
functional correlates of segregated feedforward pathways, 124–126
segregation of source neurons, 123–124
visuotopic organization, 122
Fluo 3, measurement of intracellular calcium, 439
Fluorescent tetracarboxylate indicators, measurement of intracellular calcium, 437–440
Focal adhesions, in endothelial mechanotransduction, 530–534
Food intake, humoral modulation, implications for diet-induced thermogenesis, 248
43K protein, in acetylcholine receptor protein immobilization and aggregation during formation of neuromuscular junction, 355–356
Fructose challenge, adenine nucleotide degradation during, in transgenic mice, 675–676
Fura 2, measurement of intracellular calcium, 439–440

G

Galanin, in septohippocampal pathway, 406–407
Gap junctions, 691–694
in epileptogenesis, 711–712
in low-calcium field bursts, 708–709
in mammalian central nervous system
developing CNS, 691
functional significance, 693–694
development and repair, 693
synchronization in inferior olive, 694
synchronization of hippocampal neurons, 693–694
glial gap junctions, 691–692
mature CNS, 691–693
neuronal gap junctions, 692–693
possible clinical roles, 694
in nonmammalian vertebrates, 691
Gastric acid secretion, 155–180
gastric hydrogen-potassium-adenosinetriphosphatase, 167–178
activation of, 175–176
enzymatic properties, 173
function, 173–175
identification as gastric proton pump, 174–175
inhibition of, 176–178
structure, 168–173
α-subunit, 168–171
β-subunit, 171–172
α,β-subunit association, 172–173
synthesis and turnover, 176
tertiary structure, 173
transport properties, 173–174
historical perspective, 155–156
parietal cell homeostasis, 178–180
basolateral transporters, 179
general considerations, 178–179
homeostatic responses, 179–180
regulation, 156–167
acetylcholine release, 157–158
cellular regulation, 162–167
central regulation, 156–157
control of gastric acidity, 160–162
gastrin release, 160–162
histamine release, 158–160
intracellular coupling, 165–167
parietal cell receptors, 162–165
peripheral regulation, 157–162
Gastrin, regulation of gastric acid secretion, 160–162
Gastrin receptor, parietal cell, 164
G cells, antral, gastrin release, 160–162
Genetics
molecular regulation of vascular smooth muscle cell differentiation, 504–508
surfactant protein B gene, 753–754
techniques for genetically manipulating the mouse. *See also* Transgenic mice
mapping genetic traits, 671–672
microinjection of transgenes, 668–670
problems with use of transgenic mice, 683–684
targeted gene disruption, 670–671
Geniculate body, lateral, extraocular proprioceptors and binocular integration, 328
Gephyrin, 848–849
Glucagon
communication of nutritional status to liver, 51
thermogenesis, 245–246
Glucocorticoids, immune system effects, 80–81
Glucokinase, in fatty acid synthesis, 65
Glucose-6-phosphate dehydrogenase, regulation of concentration by nutritional states, fatty acid synthesis, 58
Glucose transport, in transgenic mouse, 672–673
GLUT-1 expression in skeletal muscle, 672
GLUT-4 expression in adipose tissue, 672–673
Glutamate
transport, vesicular glutamate transporters, 372–373
anion-binding site, 386
inhibition, 375
substrate specificity, 379
in visual cortex, 113–115
Glutamate receptors, in visual cortex, 114–115
G proteins
in endothelial mechanotransduction, 534–535
heterotrimeric G proteins, 866–868
Gα, 866–867
G$\beta\gamma$, 867–868
ion channel regulation, 865–879
delineating pathway between receptor and ion channel, 869–871
demonstrating direct regulation, 871–872
diffusible second messengers in, 869–870
linking G proteins to ion channel regulation, 868–869
membrane-delimited, 870–871
calcium channels, 875–877
chloride channels, 878–879
potassium channels, 872–875
sodium channels, 877–878
Grafts, in central nervous system, septohippocampal model, 409
Growth factors, in septohippocampal pathway, 407
Growth hormone, immune system effects, 83–84
Guanosine 3′,5′-cyclic monophosphate, (cGMP)
airway actions of vasoactive intestinal peptide, 294
binding
PDE5 phosphodiesterase and, 738
PDE6 phosphodiesterase and, 739
PDE2 phosphodiesterase and, 734
PDE3 phosphodiesterase and, 735
Gut-associated lymphoid tissue. *See* Lymphoid organs

H

Helicobacter pylori toxicity, 583
Hemodynamic shear stress
effect on calcium fluxes of venous smooth muscle and endothelial cells, 631

endothelial response mechanisms. *See* Endothelial transduction
vasoregulation, 544–548
Hepatocyte canalicular membrane
adenosine 5′-triphosphate-dependent transport systems, 264–269
bile acid transporter, 266–267
multidrug resistance gene products, 264–266
transporter for nonbile acid organic ions, 267–269
mdr2 and *mdr3* expression, 265
mdr2 and phospholipid transport, 265–266
transport adenosinetriphosphatases, 261–264
calcium-magnesium ATPase, 262–263
ectoadenosinetriphosphatase, 263–264
P-type ion-transporting ATPases, 261–263
regulation/modulation, 269
sodium-potassium ATPase, 261–262
Hereditary surfactant protein B deficiency, 754–755
animal models, 755
Hippocampus. *See also* Septohippocampal pathway
synchronization of neurons, gap junctions and, 693–694
Histamine
in local control of venous tone, 642–643
in penile erection, 217
regulation of gastric acid secretion, 158–160
in shear stress-mediated vasoregulation, 548
Histamine receptor, parietal cell, 163
Histidine residues, role in structure and function of vesicular neurotransmitter transporters, 385–386
Histones, modulation of epithelial permeability, 576
Hormones
communication of nutritional status to liver, 50–53
culture studies, 52–53
in vivo studies, 50–52
gonadal. *See* Sex hormones/steroids
in local control of venous tone, 633–645
modulation of food intake, implications for diet-induced thermogenesis, 248
neuroendocrine, immune system effects, 80–86
in thermogenesis. *See* Thermogenesis
5-Hydroxytryptamine (5-HT). *See* Serotonin
Hyperglycemia, in insulin-resistant subjects. *See* Diabetes mellitus, non-insulin-dependent
Hyperinsulinemia
chronic. *See* Syndrome X
compensatory, insulin resistance and, 473–474
Hypertension
alterations in vascular smooth muscle cell differentiated state, 509
calcium fluxes of venous smooth muscle cells in, 631
in syndrome X, 479
venous wall sodium content in, 624–625
Hypertriglyceridemia, in syndrome X, 479
Hyperuricemia, in syndrome X, 480–481
Hypothalamic-pituitary-adrenal axis, immune system interactions, 80–82

I

Immune system
cellular effects of tachykinins and vasoactive intestinal peptide, 288–290
nervous system interactions. *See* Central nervous system-immune system interactions
neuroendocrine hormone production, 97
role of veins in organ-specific distribution of circulating effector lymphocytes, 614–615
Indo 1, measurement of intracellular calcium, 439–440
Inferior olive, synchronization of neurons, gap junctions and, 694
Inflammatory cells, effects of tachykinins and vasoactive intestinal peptide, 288–290
Insulin
action of, PDE3 phosphodiesterase in, 736–737
communication of nutritional status to liver, 50–51
thermogenesis, 247
Insulin resistance, 473–483
conpensatory hyperinsulinemia and, 473–474
non-insulin-dependent diabetes mellitus, 474–478
adipose tissue in, 476–477
β-cell in, 474–476
liver in, 477–478
muscle in, 474
syndrome X, 478–483
Integrins
in differentiated vascular smooth muscle cells, 495
in endothelial mechanotransduction, 530–534
Interferon(s), INF-γ, modulation of epithelial permeability, 570
Ion(s). *See also specific ions*
in extracellular fluid, nonsynaptic interactions and, 704–705
fluctuations, in low-calcium field bursts, 709
in local control of venous tone, 622–633
Ion channels
in differentiated vascular smooth muscle cells, 495
G protein regulation, 865–879. *See also* G proteins; *specific ion channels*
mechanosensitive, in endothelial mechanotransduction, 528–530
in penile erection, 208
stretch-activated, in endothelial mechanotransduction, 529–530

K

Kidney
cellular calcium transport. *See* Renal calcium transport
sodium handling, atrial natriuretic peptide in, PDE5 phosphodiesterase and, 738

L

Lactate, in local metabolic control of veins, 622
Learning, septohippocampal system in, 409–411
Legionella pneumophila toxicity, 583–584
Lipemia, postprandial, in syndrome X, 480
Lipogenesis. *See* Fatty acid synthesis
Lipoprotein, low-density, particle size, in syndrome X, 480
Liver
fatty acid synthesis, 47–49. *See also* Fatty acid synthesis
hepatocyte canalicular membrane transport adenosinetriphosphatases, 261–269. *See also* Hepatocyte canalicular membrane
mitochondrial creatine kinase, in transgenic mice, 682–683
in non-insulin-dependent diabetes mellitus, 477–478
regulation of adenosine 5′-triphosphate production in transgenic mice
creatine kinase as ADP biosensor in liver, 673–675
regulation of oxidative phosphorylation in, 676–678
Long-term potentiation, 778–782
background, 778
induction of, 778
later phases of induction and consolidation of, 778–779
model compatible with most of the conflicting data, 779–781
compelling features of model, 781

effect of such a model, 781
testable predictions of model, 782
Lung
alveolar epithelial-microvascular permeability, neuropeptide effects, 299–300
autonomic innervation, neuropeptides in, 279
neuropeptides, 278–279
surfactant protein B, 749–756
surfactant synthesis and secretion, neuropeptide effects, 300–301
Lung cancer
small-cell, cell growth and proliferation, neuropeptides and, 301
vasoactive intestinal peptide in, 304–305
Lung injury, vasoactive intestinal peptide in, 304
Lymph nodes. *See* Lymphoid organs
Lymphoid organs, sympathetic noradrenergic innervation, 87–90

M

Magainins, modulation of epithelial permeability, 578
Magnesium, in local control of venous tone, 632
Malic enzyme, regulation of concentration by nutritional states, fatty acid synthesis, 63–65
Mauthner cell, ephaptic field interactions in, 697–698
Medial septum. *See* Septohippocampal pathway
Medulla, respiratory neurons, 8–11
Memory, septohippocampal system in, 409–411
Metallochromic indicators, measurement of intracellular calcium, 435–437
Metavinculin, in differentiated vascular smooth muscle cells, 494
Microelectrodes, calcium-selective, measurement of intracellular calcium, 431–432
Microtubule assembly
building the biological structure of the cytoplasm, 837–839
historical overview, 835–837
microtubule-associated proteins in. *See* Microtubule-associated proteins
Microtubule-associated proteins, 835–857, 839–841
biochemical characterization, 841–842
building the biological structure of the cytoplasm, 837–839
cell cycle-dependent proteins linked to microtubule system, 853–856
nuclear proteins that associate with mitotic apparatus, 854–856
passenger proteins, 853–854
in *Drosophila melanogaster,* 849
echinoderm MAPs, 850
epithelial cell line MAPs, 851
gephyrin, 848–849
heat-stable, from bovine pancreas, 851
interaction with tubulin molecule, 842–844
microtubule-interacting proteins, 851–853
molecular properties, 841–844
new proteins, 848–851
in plants, 849
in regulating interaction patterns of filamentous components involved in cytoskeleton organization, 847–848
MAP interactions with intermediate filaments, 848
mediation of microtubule-actin filament interactions, 847–848
regulation of MAP function, 844–848
alternative splicing as regulatory mechanism, 844–846
posttranslational modifications in, 846–847
squid MAPs, 851
Trypanosoma brucei MAPs, 851
from *Xenopus* eggs, 850–851
Microtubule-interacting proteins, 851–853
B1K1, 853
cytoplasmic linker proteins, 852
in mammalian cultured cell lines, 853
p150^{Glued} and Glued cytoplasmic dynein-associated protein, 852
Mitosis, cell cycle-dependent proteins linked to microtubule system, 853–856
Monoamines, transport, vesicular neurotransmitter transporters, 371–372
cloning, functional expression and subtypes, 377–379
inhibitors, 374–375
members of toxin-extruding antiporter superfamily, 381–384
substrate specificity, 379–381
Motoneuron cell death, during development, 807–810
Motor end plate. *See* Neuromuscular junction
Multidrug resistance (MDR)
Bacillus, reserpine inhibition, 381
hepatocyte canalicular membrane adenosine 5′-triphosphate-dependent transport systems in, 264–266
hepatocyte canalicular membrane expression of *mdr2* and *mdr3,* 265
reserpine inhibition, 381
Muscle
creatine kinase, in transgenic mice, 679–682
early development, 790–791
embryogenesis, 790–791
fiber differentiation, 791
GLUT-1 expression, in transgenic mouse, 672
insulin resistance, in non-insulin-dependent diabetes mellitus, 474
in local metabolic control of veins, 620
smooth. *See* Smooth muscle
Myosin heavy chains, in differentiated vascular smooth muscle cells, 490–491
Myosin light chains, in differentiated vascular smooth muscle cells, 491–492

N

Natural killer cells, modulation of epithelial permeability, 573–574
Nerve compression, ephaptic transmission in, 696–697
Nerve-muscle interaction, 789–821
avian neuromuscular connections, 791–794
growth cone behavior and regions of decision making, 791–792
guidance and recognition molecules, 792–793
guidance by inhibition, 793–794
probable role of diffusible substances and electrical gradients, 794
axonal pathfinding, 791–795
avian neuromuscular connections, 791–794
Drosophila nerve-muscle preparations, 794–795
new nerve-muscle preparations, 794–795
zebra fish nerve-muscle preparations, 794
growth and plasticity of neuromuscular connections, 815–821
adjustment to changes in motor unit size, 817–818
maintaining a match between nerve and muscle, 815
number and spacing of junctions, 818
sprouting and terminal remodeling, 818–819
structure-function correlates of mature synapses, 815–816
motoneuron cell death during development, 807–810
dependence of mature motoneurons on the periphery, 809–810
neurotrophic substances, 807–808
perinatal motoneuron vulnerability, 809
role of activity, 807
muscle development, 790–791
synapse elimination/rearrangement, 810–815
mechanisms of competition, 811–814
role in refinement of connections, 810–811

role of activity in, 811
synapse elimination after reinnervation, 811
timing and phenomenology, 810
visualization of synapse elimination in vivo, role of muscle fiber in, 814–815
synaptogenesis, 795–807
exclusion of multiple end plates and precise reinnervation of old end plates, 806
initial nerve-muscle contact, 798–799
neural control of acetylcholine receptor localization and properties, 801–805
agrin and localized aggregation of AChR, 801–803
neural regulation of AChR gene expression, 803–805
stabilization of junctional AChRs, 805
neural control of other muscle membrane properties, 806–807
overview, 795–798
physiological properties of growth cones and retrograde feedback from muscle cells, 799–800
regulation of synapse-specific acetylcholinesterase and other molecules, 805
transmitter release at newly formed synapses, 800–801
Neuroendocrine hormones
immune system effects, 80–86
adrenocorticotropic hormone, 81–82
glucocorticoids, 80–81
gonadal steroids, 85–86
growth hormone, 83–84
opioid peptides, 82–83
posterior pituitary hormones, 86
prolactin, 84–85
thyroid hormones, 85
thyroid-stimulating hormone, 85
immune system production, 97
Neurokinin A. *See* Tachykinins
Neurokinin B. *See* Tachykinins
Neurokinins, in local control of venous tone, 643
Neuromas, ephaptic transmission in, 697
Neuromedin K. *See* Tachykinins
Neuromodulators, in control of respiratory central pattern generator, 18–22
Neuromuscular junction
acetylcholine receptor gene expression, 339–359
compartmentalization during end-plate development, 341–352
AChR subunit mRNA compartmentalization, 341–343
basal lamina in, 346–347
first and second messengers in, 343–347
neural factors in, 345–346
regulation by electrical activity, 343–345
regulation of promotors of AChR subunit genes, 347–352
posttranslational mechanisms during end-plate development, 352–357
AChR biosynthesis and secretory pathway, 356–357
aggregation of AChR protein, 353–355
importance of cytoskeleton for immobilization and aggregation of AChR, 355–356
metabolic stabilization of AChR, 357
dynamics of nerve-muscle interaction, 789–821. *See also* Nerve-muscle interaction
postsynaptic domain of motor end plate, 340–341
adult motor end plate, 340
motor end plate during development, 340–341
quantal analysis, 771–773
Neurons
in breathing control. *See* Respiratory neurons
nonsynaptic interactions. *See* Nonsynaptic interactions
sensitivity to electric fields, 699–703. *See also* Nonsynaptic interactions
septohippocampal
pharmacology, 403–407
physiological characteristics, 399–402
Neuropeptides
in altered airway physiology, 301–303
in autonomic innervation of lung, 279
in central regulation of nonshivering thermogenesis, 243
in control of respiratory central pattern generator, 20–22
functional roles, 278
in inflammatory and immune processes, 90–91
in the lung, 278–279
modulation of food intake, implications for diet-induced thermogenesis, 248
in penile erection, 213–216
potential therapeutic value in airway disease, 303–305
regulation of airway function, 277–306. *See also* Tachykinins; Vasoactive intestinal peptide
actions on airway smooth muscle tone and airway reactivity, 284–286
airway receptors, 292–293
airway smooth muscle proliferation, 291
airway smooth muscle tone and airway reactivity, 297–299
alveolar epithelial-microvascular permeability, 299–300
cell growth and proliferation, 301
chemical nature, molecular forms, and biosynthesis, 282–283
coexistence with other neuropeptides and neurotransmitters, 283–284
effects on inflammatory and immune cells, 288–290
enzymatic degradation of airway peptides, 295–297
influence on airway secretions, 287–288
interactions between neuropeptides and other neurotransmitters, 291–292
localization, distribution, and origins of airway neuropeptides, 279–282
mechanism of airway relaxation and constriction, 293–295
in plasma protein extravasation, 286–287
pulmonary and bronchial circulations, 290–291
surfactant synthesis and secretion, 300–301
in septohippocampal pathway, 397–398
colocalizations with neurotransmitters, 398
in visual cortex, 118
Neuropeptide Y
in local control of venous tone, 634–635
in penile erection, 214
Neurotensin, in local control of venous tone, 635
Neurotransmission
acetylcholine receptor gene expression at neuromuscular junction, 339–359
dynamics of nerve-muscle interaction at neuromuscular junction, 789–821. *See also* Nerve-muscle interaction
fast central synapses. *See* Central synaptic transmission
nonsynaptic interactions between neurons, 689–715. *See also* Nonsynaptic interactions
in penile erection, 196–217
septohippocampal cholinergic pathway, 393–412
vesicular neurotransmitter transporters, 369–388. *See also* Vesicular neurotransmitter transporters
Neurotransmitters
excitatory, in visual cortex, 113–115
inhibitory, in visual cortex, 115
in penile erection, 201–206
in respiratory central pattern generator, 16–18
in septohippocampal pathway, 395–397
colocalizations with neuropeptides, 398
transport proteins. *See* Vesicular neurotransmitter transporters

Neurotrophins
in motoneuron cell death during development, 807–808
in septohippocampal pathway, 407
Neutral endopeptidase, degradation of airway neuropeptides, 295–297
tachykinins, 296–297
vasoactive intestinal peptide, 295–296
Neutrophil-derived proteins, modulation of epithelial permeability, 572–573
Nitric oxide
airway actions of vasoactive intestinal peptide, 294
airway smooth muscle tone and airway reactivity, 297–298
interactions with vasoactive intestinal peptide, 291–292
in local control of venous tone, 639–641
in penile erection, 210–213
in shear stress-mediated vasoregulation, 544–546
Nonsynaptic interactions, 689–715
electrotonic (gap) junctions, 691–694. *See also* Gap junctions
in developing mammalian central nervous system, 691
functional significance in mammalian central nervous system, 693–694
in mature mammalian central nervous system, 691–693
in nonmammalian vertebrates, 691
ephaptic transmission between specific neurons, 694–699
background, 694–695
conditions necessary for, 695
in demyelination, 695–696
dendritic bundles, 699
ephaptic field interactions in normal vertebrates, 697–699
ephaptic transmission between axons, 695–697
in nerve compression, 696–697
in neuroma, 697
in epilepsy, 710–714. *See also* Epilepsy
extracellular ions in, 704–705
functional significance, 709–714
epilepsy, 710–714
normal evoked potentials, 709–710
normal spontaneous activity, 710
low-calcium field bursts, 705–709
form and distribution, 706
ionic fluctuations in, 709
mechanisms of, 707
field effects, 707
gap junctions, 708–709
necessary conditions for, 706–707
pharmacology of, 709
population field interaction in populations of neurons, 704–705
sensitivity of neurons to electric fields, 699–703
assessing the roles of electric fields, 703
biologic effects of electric fields, 702–703
electrical stimulation, 699
modification of neuronal growth and structure by electric fields, 702
sensitivity of mammalian cortex to electric fields, 701–702
tissue conductivity, 699–700
Norepinephrine. *See also* Catecholamines
nonshivering thermogenesis, 238–243
in penile erection, 203–204
Nuclear magnetic resonance, fluorine-19, measurement of intracellular calcium, 442–443
Nutritional status, humoral factors communicate nutritional state to liver, 50–55
fuels and metabolites in vivo and in culture, 53–55
hormones in culture, 52–53
hormones in vivo, 50–52

O

Obesity, syndrome X and, 481
Olfaction
role of PDE1 phosphodiesterases, 733–734
role of PDE2 phosphodiesterases, 735
Opiates, in local control of venous tone, 644
Opioid peptides
in control of respiratory central pattern generator, 20–21
immune system effects, 82–83
in penile erection, 204
Organic anions, nonbile acid, hepatocyte canalicular membrane adenosine 5′-triphosphate-dependent transport, 267–269
Orientation selectivity, development
role of eye movements and extraocular muscle proprioception, 324–326
role of vision, 324
Orienting behavior, development, 329–330
Osmolarity, in local metabolic control of veins, 622
Oxidative phosphorylation, hepatic, in transgenic mice, 676–678
Oxygen, in local metabolic control of veins, 620–621
Oxygen free radicals, in shear stress-mediated vasoregulation, 548
Oxytocin
immune system effects, 86
in penile erection, 204–205

P

Palytoxin, modulation of epithelial permeability, 578–579
Pancreas, bovine, microtubule-associated proteins from, 851
Parathyroid hormone, regulation of renal calcium transport, 448–450
Parathyroid hormone-related peptide, regulation of renal calcium transport, 450–452
Parietal cell
gastric acid secretion, 162–165
homeostasis, 178–180
basolateral transporters, 179
general considerations, 178–179
homeostatic responses, 179–180
Passenger proteins, 853–854
Pco_2, in local metabolic control of veins, 622
Penile erection
anatomy and morphological basis, 191–194
blood supply, 192–193
corporeal smooth muscle, 193–194
gross anatomy, 191–192
retractor penis muscle, 192
central control, 200–206
cerebral mechanisms, 200–201
neurotransmitters involved in erection, 201–206
spinal mechanisms, 200
hemodynamics, 194–196
in vitro studies, 206
neuroanatomy and neurophysiology, 196–206
central control, 200–206
peripheral control, 196–200
neurotransmitters in, 201–206
adrenocorticotropic hormone and related peptides, 205
γ-aminobutyric acid, 205–206
dopamine, 202–203
5-hydroxytryptamine, 201–202
norepinephrine, 203–204
opioids, 204

oxytocin, 204–205
prolactin, 205
peripheral nervous system control, 196–200
parasympathetic pathways, 198
somatic pathways, 198–200
sympathetic pathways, 196–198
peripheral neurotransmission and mechanisms of activation, 206–217
adenosine 5′-triphosphate and adenosine in, 217
adrenergic mechanisms, 208–209
calcitonin gene-related peptide in, 215
cholinergic mechanisms, 209–210
electrophysiology, 206–207
endothelins in, 213–214
histamine in, 217
5-hydroxytryptamine in, 217
ion channels, 208
myogenic activity, 207–208
neuropeptides in, 213–216
neuropeptide Y in, 214
nitric oxide in, 210–213
nonadrenergic noncholinergic mechanisms, 210–217
prostanoids in, 216–217
substance P in, 215–216
vasoactive intestinal polypeptide in, 214–215
vasopressin in, 214
phases, 195–196
physiology, 191–219
sex hormone effects, 217–218
central effects, 217–218
peripheral effects, 218
Penis
anatomy, 191–194
blood supply, 192–193
arterial supply, 192–193
venous drainage, 193
corporeal smooth muscle, 193–194
retractor penis muscle, 192
Peptide thermogenesis, 247
Perforin, modulation of epithelial permeability, 573–574
Peripheral nervous system, in penile erection, 196–200
p150^{Glued}, 852
P-glycoprotein
mechanism of function, 264–265
in multidrug resistance, 264–266
mechanism of function, 264–265
in normal tissues, 265
purification and reconstitution, 266
pH
in local metabolic control of veins, 622
vesicular neurotransmitter transporters, 370–374
acetylcholine transport, 373–374
amino acid transport, 372–373
monoamine transport, 370–372
Phosphate, in local metabolic control of veins, 621–622
Phosphodiesterase. *See* Cyclic nucleotide phosphodiesterases
6-Phosphofructo-1-kinase, in fatty acid synthesis, 65
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase, in fatty acid synthesis, 65
6-Phosphogluconate dehydrogenase, in fatty acid synthesis, 65
Phosphoinositides, airway actions of vasoactive intestinal peptide, 294
Phospholipids, alveolar, functions, surfactant protein B and, 751–753
Phosphorylation
PDE4 phosphodiesterase regulation, 737–738
PDE5 phosphodiesterase regulation, 738
regulation of PDE1 phosphodiesterases, 732
Phosphorylation-dephosphorylation
fatty acid synthesis regulation, 56–57
PDE3 phosphodiesterase regulation, 736
Photoproteins, calcium-sensitive, measurement of intracellular calcium, 432–435
Physical activity, syndrome X and, 481
Pituitary gland, posterior, hormones, immune system effects, 86
Plant cells, microtubule-associated proteins from, 849
Plasma protein extravasation, neuropeptide actions, 286–287
Plasminogen activator inhibitor-1, in syndrome X, 480
Plasticity
central synaptic transmission, morphological changes correlated with, 770
role of PDE1 phosphodiesterases, 732
Platelet aggregation, PDE3 phosphodiesterase in, 735
Po_2, in local metabolic control of veins, 620–621
Polymorphonuclear leukocytes, interactions with venular endothelium, 615
Pons, respiratory neurons, 11–12
Potassium
in local control of venous tone, 625–628
in local metabolic control of veins, 622
Potassium channel(s)
ATP-sensitive, in local control of venous tone, 626–627
calcium-activated, in local control of venous tone, 626
cardiac ATP-sensitive, G protein regulation, 874–875
cardiac muscarinic-gated, G protein regulation, 872–874
G protein regulation, membrane-delimited, 872–875
in penile erection, 208
shear stress-activated, in endothelial mechanotransduction, 529
Potassium channel openers, in local control of venous tone, 625–626
Potassium competitive inhibitors, inhibition of gastric proton pump, 177–178
Potassium currents
in breathing control
calcium-dependent currents, 24–25
noninactivating currents, 25
delayed rectifier, background, and transient, in local control of venous tone, 627–628
Prolactin
immune system effects, 84–85
in penile erection, 204–205
Prostacyclin, in shear stress-mediated vasoregulation, 546
Prostaglandin(s)
in local control of venous tone, 637–639
in penile erection, 216–217
in shear stress-mediated vasoregulation, 546
Prostanoids
in local control of venous tone, 637–639
in penile erection, 216
Protamine, modulation of epithelial permeability, 574–576
Proteases
degradation of airway neuropeptides, 295–297
modulation of epithelial permeability, 566–569
pathophysiological role, epithelial function and, 569
physiological role, epithelial function and, 567–569
Protein kinase, mitogen-activated, in endothelial mechanotransduction, 535
Protein kinase C, regulation/modulation of canalicular transport ATPases, 269
Proton pump, gastric. *See* Adenosinetriphosphatase, hydrogen-potassium
Pseudomonas aeruginosa toxicity, 584

Pudendal nerve, in penile erection, 198–200
Pulmonary circulation, neuropeptide actions, 290–291
Pulmonary hypertension, vasoactive intestinal peptide in, 304
Pulmonary vascular resistance, PDE5 phosphodiesterase and, 738
Purkinje cell, cerebellar, ephaptic field interactions in, 698
Pyramidal cells, visual cortex, 111–112
L-Pyruvate kinase, regulation of concentration by nutritional states, fatty acid synthesis, 60–61

Q

Quantal analysis, 771–773
Quin 2, measurement of intracellular calcium, 439

R

Receptors, in differentiated vascular smooth muscle cells, 495–496
Renal calcium transport, 429–461
  connecting tubule, 447
  cortical collecting tubule, 447–448
  distal convoluted tubule, 446–447
  measurement of calcium, 430–443
    bioluminescent indicators, 432–435
    calcium ion activity vs. calcium concentration, 430–431
    calcium-selective microelectrodes, 431–432
    electron-probe X-ray microanalysis, 440–442
    fluorescent tetracarboxylate indicators, 437–440
    metallochromic indicators, 435–437
    nuclear magnetic resonance and fluorine-labeled indicators, 442–443
  mechanisms of calcium movement across plasma membranes, 455–461
    apical entry mechanisms, 455–458
      calcium channels, 455–457
      carrier-mediated calcium entry, 457–458
    basolateral efflux mechanisms, 458–461
      calcium-adenosinetriphosphatase, 460–461
      sodium/calcium exchange, 458–460
  medullary collecting duct, 448
  proximal convoluted tubule, 443–444
  proximal straight tubule, 444
  regulation of cellular transport, 448–455
    calcitonin and, 452–453
    1,25-dihydroxyvitamin D_3 and, 453–455
    parathyroid hormone and, 448–450
    parathyroid hormone-related peptide and, 450–452
  thick ascending limbs, 445–446
  thin ascending limbs, 444–445
  thin descending limb, 444
Reserpine, inhibition of vesicular neurotransmitter transporters, 374
Respiratory neurons
  in central pattern generator functions, 25–27
  characterization, 2–8
    axonal projections, 5–7
    discharge patterns, 3–5
    responses to activation of peripheral and central afferents, 7–8
  intrinsic membrane properties and genesis of rhythmic motor activities, 23–25
    calcium-dependent potassium currents, 24–25
    noninactivating potassium currents, 25
    postinhibitory effects and intrinsic currents, 23–24
  location and anatomic organization, 8–12
    medulla, 8–11
    other structures, 12
    pons, 11–12
    spinal cord, 11
  synaptic connections, 12–15
    antidromic mapping and labeling, 12–13
    cross-correlation and spike-triggered averaging, 13–15
    membrane potential trajectories, 15
Respiratory rhythmogenesis. *See* Breathing
Retinal disease, PDE6 phosphodiesterase in, 741
Rhod 2, measurement of intracellular calcium, 439

S

Seizures. *See* Epilepsy
Septohippocampal pathway, 393–412
  afferent projections to medial septal area, 398
  in aging, 408–409
    behavioral studies, 408–409
    cholinergic "markers" in septum and hippocampus, 408
    electrophysiological studies, 409
    medial septal neurons in aged animal, 408
  in Alzheimer's disease, 409
  anatomic organization, 394–399
  colocalizations of neurotransmitters and neuropeptides, 398
  comparison with basalocortical pathway, 411
  fimbria-fornix lesions, 407–408
    septal plasticity and behavioral recovery after, 410
  functions, 409–411
    in learning and memory, 409–411
  model for study of grafts in CNS, 409
  neuropeptide distribution, 397–398
  neurotransmitter distribution, 395–397
  noncholinergic septohippocampal projection, 406–407
    GABAergic septohippocampal pathway, 406
    neuropeptidergic septohippocampal pathway, 406–407
  pharmacological characteristics of septohippocampal neurons, 403–407
    acetylcholine release, 403–404
    mechanism of action of acetylcholine in hippocampus, 404–406
      postsynaptic effects on pyramidal neurons, 404–405
      presynaptic effects, 405–406
    noncholinergic septohippocampal projection, 406–407
  physiological characteristics of septohippocampal neurons, 399–402
    in vitro studies, 401–402
    in vivo studies, 399–401
    septal rhythmic activity, 402
  receptors of neurotransmitters, 398–399
    in hippocampal formation, 399
    in medial septum, 398–399
  response to fimbria-fornix lesions, 407–408
  role of growth factors, 407
  septal rhythmic activity, 402
  topography, 394–395
Serotonin
  in control of respiratory central pattern generator, 19–20
  in local control of venous tone, 644
  in penile erection, 201–202, 217
Sex hormones/steroids
  immune system effects, 85–86
  in penile erection, 217–218
SM-22α, in differentiated vascular smooth muscle cells, 492
Smooth muscle
  airway
    proliferation, neuropeptide actions, 291
    tone, neuropeptide actions, 284–286, 297–299
  corpus cavernosum and corpus spongiosum, 193–194
  vascular. *See also* Vascular smooth muscle cell differentiation
    calcium fluxes of venous smooth muscle
      alterations in hypertension, 631
      shear stress and, 631
    developmental origin, 496–497

Sodium
in local control of venous tone, 622–625
venous wall content, in hypertension, 624–625
Sodium/calcium exchanger, renal calcium transport, 458–460
Sodium channel(s), G protein regulation, 877–878
Somatostatin
in inflammatory and immune processes, 90
in local control of venous tone, 644–645
in visual cortex, 118
Spinal cord, respiratory neurons, 11
Spiny stellate cells, visual cortex, 112
Spleen. *See* Lymphoid organs
Squid, microtubule-associated proteins from, 851
Stereoacuity, development, 330–331
Steroid thermogenesis, 247
Strabismus, 331–332
Streptococcus spp.
pneumoniae, toxicity, 584
pyogenes, toxicity, 584
Stress
hemodynamic shear stress. *See* Endothelial mechanotransduction
nervous system-immune interactions, 78–79
Stress response elements, in endothelial mechanotransduction, 542–544
Substance K. *See* Tachykinins
Substance P. *See also* Tachykinins
in control of respiratory central pattern generator, 21–22
in inflammatory and immune processes, 90
in local control of venous tone, 643
in penile erection, 215–216
Superior colliculus, extraocular proprioceptors and binocular integration, 328
Surfactant protein B, 749–756
biosynthesis and intracellular trafficking, 750–751
cellular sites of synthesis in human lung, 750
gene, structure and regulation, 753–754
hereditary deficiency, 754–755
animal models, 755
posttranscriptional regulation, 754
role in organization and functions of alveolar phospholipids, 751–753
structure, 749–750
SV2 protein family, 387
Sympathetic nervous system
in penile erection, 196–198
regulation of nonshivering thermogenesis, 243
Synaptic transmission. *See* Neurotransmission
Syndrome X, 478–483
clinical manifestations, 479–481
coronary heart disease and, 481–483
dyslipidemia in, 479–480
high-density lipoprotein cholesterol in, 479–480
hypertension in, 479
hypertriglyceridemia in, 479
hyperuricemia in, 480–481
low-density lipoprotein particle diameter in, 480
obesity and physical activity and, 481
plasminogen activator inhibitor 1 concentration in, 480
postprandial lipemia in, 480

T

Tachykinins
airway receptors, 293
in altered airway physiology, defenders of airways or mediators of inflammation, 302–303
chemical nature, molecular forms, and biosynthesis, 282–283
in local control of venous tone, 643
potential therapeutic value in airway disease, 305
regulation of airway function
actions on airway smooth muscle tone and airway reactivity, 285–286
airway smooth muscle proliferation, 291
airway smooth muscle tone and airway reactivity, 298–299
alveolar epithelial-microvascular permeability, 300
cell growth and proliferation, 301
coexistence with other neuropeptides and neurotransmitters, 284
effects on inflammatory and immune cells, 288–290
enzymatic degradation by neutral endopeptidase and other proteases, 296–297
influence on airway secretions, 287–288, 299
interactions with acetylcholine, 292
interactions with nitric oxide, 292
interactions with other neurotransmitters, 292
localization, distribution, and origins in airways, 281–282
mechanism of airway relaxation and constriction, 294–295
in plasma protein extravasation, 286–287
pulmonary and bronchial circulations, 290–291
surfactant synthesis and secretion, 301
TetA protein, mutations, 386
Tetrabenazine, inhibition of vesicular neurotransmitter transporters, 374–375
Tetracarboxylate indicators, fluorescent, measurement of intracellular calcium, 437–440
Thermogenesis
definitions, 238
diet-induced, 248
epinephrine, 244–245
glucagon, 245–246
hormonal, 237–249
energy balance and, 244–248
mutual interactions among thermogenic hormones and their role in energy balance and thermal homeostasis, 247–248
thermoregulatory role, 244
introduction, 237–238
nonshivering, 238–243
avian, 243–244
cellular mechanisms, 241–243
central regulation and modulation by humoral substances, 243
definition, 238
estimating the magnitude of, 239–240
mammalian, 238–243
occurrence and physiological significance, 238–239
sites of, 240–241
peptide, 247
steroid, 247
thyroid, 246–247
Thermoregulation, thermogenesis and. *See* Thermogenesis
Thionins, modulation of epithelial permeability, 576–578
Thromboembolic reactions, inhibition by venous mechanisms, 615
Thrombomodulin, in endothelial mechanotransduction, 535, 537–538
Thyroid hormones
immune system effects, 85
thermogenesis, 246–247
Thyroid-stimulating hormone, immune system effects, 85
Thyrotropin-releasing hormone, in control of respiratory central pattern generator, 22
T lymphocytes
modulation of epithelial permeability, 573–574
role of veins in organ-specific distribution of circulating effector lymphocytes, 614–615
Toxin-extruding antiporter (TEXAN) superfamily, vesicular neurotransmitter transporters, 381–384

Transcription factors, in endothelial mechanotransduction, 542–544
Transgenic mice
cellular energy metabolism, 667–668, 672–683
creatine kinase in, 678–683
glucose transport, 672–673
regulation of adenosine 5′-triphosphate production, 673–678
creatine kinase in cellular energetics, 678–683
altering creatine kinase isoenzymes in muscle, 681–682
ATP buffering and cell viability, 679
background, 678
expression of mitochondrial creatine kinase in liver, 682–683
muscle without MM creatine kinase, 679–681
glucose transport, 672–673
GLUT-1 expression in skeletal muscle, 672
GLUT-4 expression in adipose tissue, 672–673
problems with use of transgenic mice, 683–684
regulation of adenosine 5′-triphosphate production, 673–678
adenine nucleotide degradation during fructose challenge, 675–676
creatine kinase as ADP biosensor in liver, 673–675
regulation of oxidative phosphorylation in liver, 676–678
techniques for genetically manipulating the mouse, 668–672
mapping genetic traits, 671–672
microinjection of transgenes, 668–670
targeted gene disruption, 670–671
Transport proteins
in neurotransmission. *See* Vesicular neurotransmitter transporters
vesicular transporters other than vesicular neurotransmitter transporters, 386–387
Triglyceride(s), in syndrome X, 479
Tropomyosin, in differentiated vascular smooth muscle cells, 494
Trypanosoma brucei, microtubule-associated proteins from, 851
Tubulin, interaction with microtubule-associated proteins, 842–844
Tumor necrosis factor-α, modulation of epithelial permeability, 569–570

V

Vascular smooth muscle cell differentiation, 487–510
alterations in vascular disease, 508–509
asynchronous, 497–498
characteristics of differentiated smooth muscle cells, 488–496
marker proteins, 489–496. *See also* Vascular smooth muscle cell differentiation, marker proteins
multifunctionality, 488–489
developmental origin of vascular smooth muscle, 496–497
factors that influence differentiated state, 501–504
cell-cell interations, 502–503
endothelial-smooth muscle cell interactions, 502–503
extracellular matrix and, 504
growth state and, 501–502
hemodynamic and/or mechanical factors, 503–504
neuronal influences, 503
future directions, 509–510
marker proteins, 489–496
α-actin, 489–490
caldesmon, 492–494
calponin and SM-22α, 492
developmental changes in expression, 497–498
integrins, 495
intermediate filament proteins, 494–495
ion channels and receptors, 495–496
metavinculin, 494
myosin heavy chains, 490–491
myosin light chains, 491–492
tropomyosin, 494
vinculin, 494
mechanisms of control of cellular differentiation, 488
molecular regulation, 504–508
additional strategies for identifying SMC differentiation control genes, 507–508
posttranscriptional control, 506–507
transcriptional control, 504–506
regulation, in vitro studies, utility of cultured smooth muscle cells, 498–501
Vascular system
hemodynamic response mechanisms in endothelium, 519–551. *See also* Endothelial mechanotransduction
local control of veins. *See* Venous system
smooth muscle cell differentiation. *See* Vascular smooth muscle cell differentiation
Vasoactive intestinal polypeptide
in airway disease, 302
in airway hyperreactivity and inflammation, 301–302
airway receptors, 292
in altered airway physiology, 301–302
chemical nature, molecular forms, and biosynthesis, 282–283
in inflammatory and immune processes, 91
in local control of venous tone, 636
in penile erection, 214–215
potential therapeutic value in airway disease, 303–305
acute lung injury and airway inflammation, 304
asthma and airway inflammation, 303–304
lung cancer, 304–305
pulmonary hypertension, 304
regulation of airway function
airway smooth muscle proliferation, 291
airway smooth muscle tone and airway reactivity, 285–286, 297–298
alveolar epithelial-microvascular permeability, 299–300
cell growth and proliferation, 301
coexistence with other neuropeptides and neurotransmitters, 283–284
effects on inflammatory and immune cells, 288–290
enzymatic degradation by neutral endopeptidase and other proteases, 295–296
influence on airway secretions, 288, 299
interactions with acetylcholine, 291
interactions with nitric oxide, 291–292
localization, distribution, and origins in airways, 281
mechanism of airway relaxation and constriction, 293–294
in plasma protein extravasation, 287
pulmonary and bronchial circulations, 290
surfactant synthesis and secretion, 300–301
in visual cortex, 118
Vasoconstriction
hormones in venoconstriction, 633–635
angiotensin II, 633–634
neuropeptide Y, 634–635
neurotensin, 635
vasopressin, 635
shear stress-mediated, endothelin-1 in, 546–548
Vasodilation
hormones in venodilation, 635–636
atrial natriuretic peptide, 635–636
calcitonin gene-related peptide, 636
vasoactive intestinal polypeptide, 636
shear stress-mediated
nitric oxide in, 544–546
prostacyclin in, 546
Vasopressin

immune system effects, 86
in local control of venous tone, 635
in penile erection, 214
Venoactive agents, calcium-dependent, in local control of venous tone, 629–631
Venous system
local control, 611–647
biomechanical aspects, 616–619
biomechanics of veins, 616–617
pressure- and flow-dependent local control of venous tone, 617–619
calcium in, 628–631
chloride in, 632–633
combination constrictor/relaxing agents in, 636–645
bradykinin, 636–637
eicosanoids, 637–639
endothelial factors, 639–642
histamine, 642–643
neurokinins, 643
opiates, 644
serotonin, 644
somatostatin, 644–645
constrictor agents in, 633–635
angiotensin II, 633–634
endothelial factors, 641–642
neuropeptide Y, 634–635
neurotensin, 635
vasopressin, 635
hormones in, 633–645
agents with both constrictor and relaxant effects, 636–645
constrictor agents, 633–635
relaxing agents, 635–636
ions in, 622–633
magnesium in, 632
metabolic control, 619–622
adenosine, adenosine 5′-diphosphate, adenosine 5′-triphosphate, and phosphate, 621–622
general aspects, 619–620
muscle and muscle work in, 621
oxygen (Po_2), 620–621
pH, Pco_2, lactate, potassium, and osmolarity, 622
physiological functions related to veins, 612–616
potassium in, 625–628
pressure- and flow-dependent local control of venous tone, 617–619
relaxing agents in, 635–636
atrial natriuretic peptide, 635–636
calcitonin gene-related peptide, 636
endothelial factors, 639–641
vasoactive intestinal polypeptide, 636
sodium in, 622–625
penis, 193
physiological functions related to veins, 612–616
angiogenesis, 613
conduits (collectors) with flow-rectifying valves, 612
cooperation between venular endothelium and polymorphonuclear leukocytes, 615
immune function: organ-specific distribution of circulating effector lymphocytes, 614–615
inhibition of thromboembolic reactions, 615
maintenance of filling pressure of heart, 613
orthostatic tolerance of organism, 613
postcapillary resistance function, 613
regulated capacity: distribution of blood flow, 612–613
selective barrier function, 612
special regional functions, 615–616
synthesis of bioactive substances in vascular wall, 614
Vesamicol, inhibition of vesicular neurotransmitter transporters, 375–376
Vesicular neurotransmitter transporters, 369–388
acetylcholine transporters, 373–374
cloning, 379
inhibition, 375–376
members of toxin-extruding antiporter superfamily, 381–384
substrate specificity, 379
functional transporters, identification of, 376–377
functions catalyzed by unknown proteins, vesicular transporters other than vesicular neurotransmitter transporters, 386–387
glutamate transporter, 372–373
anion-binding site, 386
inhibition, 375
substrate specificity, 379
inhibitors, 374–376
members of toxin-extruding antiporter superfamily, 381–384
drug-resistant branch of major facilitator superfamily, 382–384
toxin-extruding antiporters and ABC-type adenosinetriphosphatases, 384
monoamine transporters, 371–372
cloning, functional expression and subtypes, 377–379
inhibition of, 374–375
members of toxin-extruding antiporter superfamily, 381–384
substrate specificity, 379–381
open issues and unanswered questions, 387–388
pharmacology, 374–376
acetylcholine transporter, 375–376
glutamate uptake, 375
molecular mechanisms of reserpine action, 374–375
pH gradients, membrane potentials, and neurotransmitter storage, 370–374
acetylcholine transport, 373–374
amino acid transport, 372–373
monoamine transport, 371–372
proteins with unknown functions, 387
structure-function studies
anion-binding site in vesicular glutamate transporter, 386
carboxyl residues in structure and function, 385
histidine and arginine residues in structure and function, 385–386
mutations in TetA and BMR proteins, 386
residues/domains with putative roles in structure and function, 384–386
substrate specificity, 379–381
SV2 protein family, 387
transporters and neurotransmission, 370
Vibrio cholerae toxicity, 584–585
Vimentin, in differentiated vascular smooth muscle cells, 494–495
Vinculin, in differentiated vascular smooth muscle cells, 494
Vision, PDE6 phosphodiesterase in, 739
Visual cortex, extraocular proprioceptors and binocular integration, 327–328
Visual system
cortical neuronal synchronization
binding hypothesis, 140–141
within a cortical area, 135–137
between cortical areas, 137–138
evidence for cortical synchronization, 135–138
mechanisms of synchronization, 139–140
excitatory synaptic mechanisms, 139–140
inhibitory synaptic mechanisms, 140
nonsynaptic mechanisms, 140
possible roles, 140–142
routing of information in cortex, 141
structural basis, 138–140

intra-area synchronization, 138
mechanisms of synchronization, 139–140
synchronization between cortical areas, 138–139
temporal constraints of information transfer in cortex, 141–142
corticocortical connections, 107–142
cellular and synaptic characteristics, 111–118
cortical inhibitory projections, 115–117
excitatory cortical connections, 111–115
modulatory circuits, 117–118
cortical inhibitory projections, 115–117
actions of GABA, 117
inhibitory connections, 116–117
inhibitory neurons, 115–116
divergence and convergence, 118–123. *See also* Visual system, divergence and convergence
excitatory cortical connections, 111–115
excitatory cell types, 111–112
excitatory interactions, 112–113
glutamate and its receptors, 113–115
extrinsic connections, 108–110
excitatory, 113
inhibitory, 116
feedback connections, 108–110
are they more diffuse, 128–129
axonal bifurcation, 129
distribution of cells and axon terminals, 128
functional aspects assessed by inactivation or lesion studies, 132–133
reciprocity between cortical connections at level of cell patch, 128–129
visuotopic organization, 122
feedforward connections, 108–110
in cat, 130–131
functional aspects assessed by inactivation or lesion studies, 130–132
in monkey, 131–132
in other sensory modalities, 132
patchy organization, 123–127
visuotopic organization, 122
functional aspects assessed by inactivation or lesion studies, 129–135
interhemispheric connections, 110
excitatory, 113
functional aspects assessed by inactivation or lesion studies, 134–135
inhibitory, 116–117
visuotopic organization, 122
intrinsic connections, 108
excitatory, 112–113
functional aspects assessed by inactivation or lesion studies, 133–134
inhibitory, 116
patchy organization, 127–128
role of horizontal connections, 133–134
role of interlaminar connections, 133
visuotopic organization, 122
modulatory circuits, 117–118
monoaminergic, 118
peptidergic, 118
neuronal synchronization, 135–142
evidence for cortical synchronization, 135–138
possible role of cortical synchronization, 140–142
structural basis, 138–140
patchy organization of feedforward connections, 123–127
functional correlates of segregated feedforward pathways, 124–126
patchy organization of feedforward axon terminals, 126–127
segregation of source neurons, 123–124
patchy organization of intrinsic connections, 127–128
reciprocity of connections between cortical areas, 110–111
segregation of pathways, 123–129
patchy organization of feedforward connections, 123–127
types of connections, 108–111
divergence and convergence, 118–123
cell-to-cell convergence and divergence, 118–120
consequences on unitary EPSPs, 119–120
morphological estimates, 118–119
spatial aspects, 120–123
spatial reciprocity of cortical connections, 120–121
visuotopic organization, 121–123
excitatory cell types, 111–112
pyramidal cells, 111–112
spiny stellate cells, 112
extraocular proprioception, 323–334. *See also* Extraocular muscle proprioception
glutamate and its receptors in, 113–115
inhibitory neurons, 115–116
basket cells, 115–116
chandelier cells, 116
double-bouquet cells, 116
neuropeptides in, 118
orientation selectivity, 324–326
Visuomotor behavior, development, 329

X

Xenobiotics
bacterial, modulation of epithelial permeability, 579–585
antibiotics, 579–581
Bacillus subtilis toxin, 581
Bacillus thuringiensis toxin, 581
Bordetella pertussis toxin, 581
Clostridium difficile toxin, 583
Clostridium perfringens toxin, 583
Corynebacterium diphtheriae toxin, 583
Escherichia coli toxin, 583
Helicobacter pylori toxin, 583
Legionella pneumophila toxin, 583–584
Pseudomonas aeruginosa toxin, 584
Streptococcus pneumoniae toxin, 584
Streptococcus pyogenes toxin, 584
toxins, 581–585
Vibrio cholerae toxin, 584–585
nonbacterial, modulation of epithelial permeability, 576–579
magainins, 578
palytoxin, 578–579
thionins, 576–578
Xenopus, microtubule-associated proteins from, 850–851

Z

Zinc, PDE5 phosphodiesterase regulation, 738